GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NuCana PLC (NAS:NCNA) » Definitions » ROCE %

NuCana (NuCana) ROCE % : -177.56% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is NuCana ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NuCana's annualized ROCE % for the quarter that ended in Dec. 2023 was -177.56%.


NuCana ROCE % Historical Data

The historical data trend for NuCana's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NuCana ROCE % Chart

NuCana Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
Get a 7-Day Free Trial Premium Member Only -35.94 -40.64 -54.50 -78.96 -118.33

NuCana Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -133.23 -94.93 -77.96 -140.09 -177.56

NuCana ROCE % Calculation

NuCana's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-39.399/( ( (70.955 - 23.52) + (35.204 - 16.046) )/ 2 )
=-39.399/( (47.435+19.158)/ 2 )
=-39.399/33.2965
=-118.33 %

NuCana's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-41.24/( ( (42.038 - 14.744) + (35.204 - 16.046) )/ 2 )
=-41.24/( ( 27.294 + 19.158 )/ 2 )
=-41.24/23.226
=-177.56 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NuCana  (NAS:NCNA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


NuCana ROCE % Related Terms

Thank you for viewing the detailed overview of NuCana's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


NuCana (NuCana) Business Description

Traded in Other Exchanges
Address
3 Lochside Way, Edinburgh, GBR, EH12 9DT
NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by ProTide technology. Utilising proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Geographically operates through the region of the United States.

NuCana (NuCana) Headlines

From GuruFocus

NuCana Announces Receipt of NASDAQ Notice

By PurpleRose PurpleRose 07-13-2022

NuCana to Present at the Jefferies London Healthcare Conference

By Value_Insider Value_Insider 11-08-2022

NuCana Announces Receipt of NASDAQ Notice

By GuruFocusNews GuruFocusNews 06-23-2022

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

By Stock market mentor Stock market mentor 01-23-2023

NuCana to Participate in the 2022 Jefferies Healthcare Conference

By GuruFocusNews GuruFocusNews 07-01-2022

NuCana to Host Investor Meetings During the J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023